Anu Muona is a founder and CEO of Aranda. Anu has over 10 years of experience in preclinical drug development in small molecules for various target indications. Prior founding Aranda she has served as a Head of Cellular and Molecular Biology at Medeia Therapeutics Ltd, the originator of ADA-308 program, her major responsibility being the pharmacological development of the program. She has also been a member of a team exploring the potential of bone marrow stem cell-based therapy for the treatment of Alzheimer’s disease at Medeia. Anu has a strong scientific background in molecular biology and genetics. She received her PhD in molecular biology in the Collagen research unit of University of Oulu, Finland. She has completed extensive postdoctoral training in stem cell research and its applications in neurodegenerative diseases at the University of Eastern Finland, Kuopio.